VK 0612

Drug Profile

VK 0612

Alternative Names: MB 07803; VK-0612

Latest Information Update: 16 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Metabasis Therapeutics
  • Developer Viking Therapeutics
  • Class Amino acids; Antihyperglycaemics; Oxazoles; Thiazoles
  • Mechanism of Action Fructose bisphosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 21 Mar 2017 Viking Therapeutics has patent protection and a pending patent application for VK 0612 in USA, China, Hong Kong, Israel, Korea, Mexico, India, Indonesia and New Zealand
  • 30 Jun 2015 VK 0612 is still in phase II trials for Type-2 diabetes mellitus in USA
  • 22 May 2014 VK 0612 licensed to Viking Therapeutics worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top